Aplastic Anemia in HIV: Risk Factors and Prognostic Indicators

Article · September 2024

CITATIONS
0

READS
3

2 authors, including:

Emmanuel Ifeanyi Obeagu
Africa University
2,100 PUBLICATIONS **36,090** CITATIONS

SEE PROFILE

Elite Journal of Laboratory Medicine. Volume 2 Issue 9(2024), Pp. 17-28

https://epjournals.com/journals/EJLM

Aplastic Anemia in HIV: Risk Factors and Prognostic Indicators

*Emmanuel Ifeanyi Obeagu[1] and Stella Ngozika Kanu[2]

[1]Department of Medical Laboratory Science, Kampala International University, Uganda.

[2]Department of Haematology, Imo State University, Owerri, Imo State, Nigeria

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Aplastic anemia (AA) in the context of HIV infection presents unique diagnostic and therapeutic challenges due to the interplay between viral pathogenesis and hematological dysfunction. This review explores the risk factors and prognostic indicators associated with AA in HIV-positive patients. Key risk factors include HIV-induced immune dysregulation, co-infections (such as hepatitis and cytomegalovirus), and genetic predispositions, which collectively contribute to the development and exacerbation of AA. Additionally, the review examines how antiretroviral therapy (ART) and its side effects impact the risk of AA. Prognostic indicators for AA in HIV-infected individuals encompass HIV viral load, CD4+ count, response to ART, and the severity of hematological abnormalities. Elevated HIV viral loads and lower CD4+ counts are associated with worse outcomes, underscoring the importance of effective viral suppression and immune system management. The severity of AA, as determined by the degree of pancytopenia and bone marrow failure, further influences prognosis.

Keywords: *Aplastic Anemia, HIV, Risk Factors, Prognostic Indicators, Hematopoiesis*

Introduction

Aplastic anemia (AA) is a severe hematological condition characterized by the insufficient production of blood cells, leading to pancytopenia—a reduction in red blood cells, white blood cells, and platelets. This condition results from the failure of hematopoietic stem cells (HSCs) in the bone marrow to produce adequate numbers of blood cells, which can lead to symptoms such as fatigue, infections, and bleeding complications. While AA can occur as a primary disorder or

secondary to various underlying conditions, its association with HIV infection introduces additional complexities that significantly impact its diagnosis, management, and outcomes. HIV infection, which primarily targets the immune system, can have profound effects on hematopoiesis. The virus induces a state of chronic immune activation and inflammation, which can disrupt normal bone marrow function. Additionally, HIV-associated immune dysregulation can exacerbate or contribute to the development of AA. The interplay between HIV and AA involves a range of factors, including direct viral effects on hematopoietic cells, immune-mediated destruction of blood cells, and the impact of associated co-infections.[1-6]

The risk factors for developing AA in the context of HIV are multifaceted. HIV-induced immune dysregulation plays a central role, as chronic inflammation and immune activation can impair the bone marrow microenvironment, leading to hematopoietic failure. Moreover, HIV-positive individuals often experience co-infections, such as hepatitis viruses and cytomegalovirus (CMV), which further compromise bone marrow function and increase the risk of AA. The impact of these co-infections, along with the direct effects of HIV, creates a complex clinical picture that challenges conventional approaches to diagnosis and treatment. Genetic factors also contribute to the risk of AA in HIV-positive patients. Variations in genes involved in hematopoiesis and immune regulation can predispose individuals to AA. The interaction between genetic susceptibility and HIV-induced immune dysregulation highlights the need for a comprehensive approach to managing AA in the context of HIV infection.[7-12]

Antiretroviral therapy (ART), the cornerstone of HIV treatment, has significantly improved the prognosis of HIV-positive patients. However, some ART regimens can have hematological side effects, including bone marrow suppression, which may increase the risk of AA. The choice and duration of ART must be carefully managed to balance the benefits of viral suppression with the potential risks to hematopoietic function. Prognostic indicators for AA in HIV-positive patients are crucial for assessing disease severity and guiding treatment. Key indicators include HIV viral load, CD4+ count, and the severity of hematological abnormalities. Higher viral loads and lower CD4+ counts are associated with worse outcomes, emphasizing the importance of effective viral control and immune system management. Monitoring these indicators helps in predicting disease progression and tailoring treatment strategies.[13-18] The management of AA in HIV-positive patients requires a multifaceted approach that addresses both HIV control and AA treatment. This includes optimizing ART to achieve and maintain viral suppression, managing co-infections, and considering specific therapies for AA such as immunosuppressive treatments or hematopoietic stem cell transplantation (HSCT). Each of these components must be individualized based on the patient's overall health, disease severity, and response to therapy.[19-20]

HIV and Its Impact on Hematopoiesis

Human Immunodeficiency Virus (HIV) has a profound impact on hematopoiesis, the process of blood cell production in the bone marrow. The virus primarily targets the immune system, leading to a cascade of effects that disrupt normal hematopoietic function. HIV-induced immune dysregulation and chronic inflammation are central to the development of hematological abnormalities observed in HIV-positive individuals. These disruptions can manifest in various forms, including anemia, thrombocytopenia, and leukopenia, with severe cases potentially leading to aplastic anemia (AA). HIV exerts direct effects on hematopoietic stem cells (HSCs), which are

the precursors to all blood cells. The virus can infect HSCs or affect their microenvironment, leading to impaired hematopoiesis. HIV-infected HSCs may experience disruptions in normal cell differentiation and proliferation, resulting in reduced production of red blood cells, white blood cells, and platelets. The direct interaction between HIV and HSCs can contribute to the development of various hematological disorders, including AA.[21-26]

HIV infection leads to chronic immune activation and inflammation, which have detrimental effects on the bone marrow microenvironment. Elevated levels of pro-inflammatory cytokines and immune cell activation can impair the bone marrow's ability to support normal hematopoiesis. This inflammatory milieu disrupts the delicate balance required for effective blood cell production, contributing to conditions such as anemia and thrombocytopenia. The inflammatory cytokines produced in response to HIV can also have cytotoxic effects on hematopoietic cells, further exacerbating hematological abnormalities. HIV-positive individuals often have co-infections that can compound the effects of HIV on hematopoiesis. Co-infections with hepatitis viruses, cytomegalovirus (CMV), and other pathogens can further strain the bone marrow and immune system, leading to more severe hematological complications. These co-infections may contribute to or exacerbate the development of AA by introducing additional sources of inflammation and immune dysregulation. The interplay between HIV and co-infections underscores the need for comprehensive management strategies to address both the primary viral infection and associated complications.[27-32]

Antiretroviral therapy (ART) is essential for controlling HIV infection and improving overall health outcomes. However, some ART regimens can have hematological side effects, including bone marrow suppression. Drugs that impact blood cell production or function can increase the risk of developing hematological disorders such as AA. The choice of ART regimen and careful monitoring of its effects on hematopoiesis are critical to minimize the risk of drug-induced bone marrow suppression and maintain optimal blood cell counts. Genetic and epigenetic factors can also influence how HIV affects hematopoiesis. Variations in genes involved in immune regulation and hematopoiesis may predispose individuals to more severe hematological complications in the context of HIV infection. Epigenetic modifications resulting from chronic HIV-induced inflammation can alter gene expression patterns related to hematopoiesis, potentially contributing to the development of AA. Understanding these genetic and epigenetic influences is important for identifying individuals at higher risk and developing targeted interventions.[33-38] Effective management of HIV-related hematological disorders requires regular monitoring of blood cell counts and overall hematological health. Early detection of abnormalities allows for timely intervention and adjustment of treatment strategies. Monitoring parameters such as CD4+ count, HIV viral load, and the impact of ART on hematopoiesis is crucial for managing both HIV and its associated hematological complications. A multidisciplinary approach that includes hematologists, infectious disease specialists, and pharmacologists is often necessary to address the complex interactions between HIV and hematopoiesis.[39-40]

Risk Factors for Aplastic Anemia in HIV

Aplastic anemia (AA) in HIV-positive patients is influenced by a range of risk factors that interplay with the underlying HIV infection. These risk factors can be broadly categorized into HIV-specific factors, co-infections, treatment-related factors, and genetic predispositions. Understanding these

risk factors is crucial for identifying individuals at higher risk and tailoring prevention and management strategies. HIV infection leads to chronic immune activation and dysregulation, which significantly impacts bone marrow function. The virus causes persistent inflammation and immune system alterations that disrupt normal hematopoiesis. Elevated levels of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), can impair the bone marrow microenvironment, reducing the production of blood cells and increasing the risk of AA. HIV-induced immune dysregulation can lead to a condition known as immune-mediated bone marrow failure, where the immune system erroneously targets and destroys hematopoietic cells.[41-46]

Co-infections with other pathogens are prevalent in HIV-positive individuals and contribute to the risk of developing AA. Hepatitis viruses (such as hepatitis B and C) and cytomegalovirus (CMV) are common co-infections that can exacerbate immune dysregulation and cause additional strain on the bone marrow. Hepatitis viruses can induce chronic liver inflammation, which affects blood cell production, while CMV infection can lead to direct bone marrow suppression. These co-infections may not only worsen the clinical course of AA but also complicate its diagnosis and treatment. While ART is essential for managing HIV infection and improving patient outcomes, some ART regimens are associated with hematological side effects that can increase the risk of AA. Certain antiretroviral drugs, such as zidovudine (AZT), have been linked to bone marrow suppression and anemia. Long-term use of these drugs can lead to cumulative toxicity, impacting hematopoietic function and contributing to the development of AA. Monitoring the hematological effects of ART and adjusting treatment as needed is critical to mitigating these risks.[47-52]

Genetic predispositions play a role in the susceptibility to AA in the context of HIV. Variants in genes involved in hematopoiesis, immune regulation, and DNA repair mechanisms can influence an individual's risk of developing AA. Additionally, epigenetic changes induced by chronic HIV infection and associated inflammation may alter gene expression patterns related to hematopoiesis. HIV-positive individuals are at increased risk of nutritional deficiencies due to the virus's impact on metabolism and gastrointestinal function. Deficiencies in essential nutrients, such as vitamin B12, folate, and iron, can impair hematopoiesis and contribute to the development of anemia. Addressing nutritional deficiencies through supplementation and dietary interventions can help mitigate the risk of AA and improve overall hematological health. Immune Reconstitution Inflammatory Syndrome (IRIS) is a condition that can occur in HIV-positive individuals undergoing ART. As the immune system recovers, it can mount an exaggerated inflammatory response to previously controlled infections or latent pathogens. This inflammatory response can adversely affect the bone marrow and increase the risk of AA. Managing IRIS involves careful monitoring and adjustment of ART to balance immune recovery with the risk of exacerbating hematological complications.[53-58] Exposure to environmental toxins and medications, such as certain chemotherapy agents and radiation, can further increase the risk of AA in HIV-positive individuals. These toxins can cause direct damage to the bone marrow or interact with HIV-related factors to exacerbate hematopoietic failure. Reducing exposure to such toxins and monitoring for their effects is important in managing the risk of AA. Other comorbid conditions prevalent in HIV-positive individuals, such as autoimmune disorders or malignancies, can contribute to the development of AA. Autoimmune diseases can cause the immune system to attack hematopoietic cells, while malignancies can directly involve the bone marrow or induce secondary AA.

Addressing these comorbid conditions through appropriate treatment and management is crucial for reducing the risk of AA.[59-63]

Prognostic Indicators for Aplastic Anemia in HIV

These indicators encompass various clinical, immunological, and hematological factors that reflect the severity of AA and the impact of HIV on disease progression. Here are key prognostic indicators for AA in HIV:

1. HIV Viral Load

HIV viral load is a critical prognostic indicator in AA management. High viral loads are associated with worse outcomes due to increased immune system activation and inflammation. Elevated viral loads can exacerbate bone marrow dysfunction and impair hematopoiesis, contributing to the severity of AA. Effective antiretroviral therapy (ART) aiming to achieve and maintain undetectable viral loads is essential for improving prognosis and managing AA in HIV-positive patients.[66-64]

2. CD4+ Count

CD4+ count is a marker of immune system function and is closely linked to the progression of HIV and related complications. A low CD4+ count is indicative of advanced immunosuppression, which can worsen AA and increase susceptibility to infections and other complications. Monitoring CD4+ counts help in assessing immune status and guiding treatment decisions, including the need for ART optimization and management of AA.[65-67]

3. Severity of Hematological Abnormalities

The severity of hematological abnormalities in AA is a crucial prognostic factor. Parameters such as the degree of pancytopenia (reduction in red blood cells, white blood cells, and platelets) and the presence of severe anemia or thrombocytopenia can indicate the severity of bone marrow failure. The extent of hematological impairment affects the overall prognosis and guides therapeutic interventions, such as the need for transfusions, immunosuppressive therapy, or hematopoietic stem cell transplantation (HSCT).[68-70]

4. Response to Antiretroviral Therapy (ART)

The effectiveness of ART in controlling HIV and its impact on AA are important prognostic indicators. A favorable response to ART, characterized by sustained viral suppression and improvement in CD4+ counts, is associated with better outcomes in AA management. Conversely, suboptimal ART response or the development of drug resistance can worsen AA and complicate treatment. Regular monitoring of ART efficacy and adherence is essential for optimizing outcomes.[71-74]

5. Co-Infections and Comorbidities

The presence of co-infections (e.g., hepatitis viruses, cytomegalovirus) and comorbid conditions can significantly influence the prognosis of AA in HIV-positive patients. Co-infections can exacerbate immune dysregulation and bone marrow suppression, while comorbidities such as autoimmune disorders or malignancies can further complicate the clinical picture. Addressing and managing these additional health issues is crucial for improving overall prognosis.[75-77]

Citation: Obeagu EI, Kanu SN. Aplastic Anemia in HIV: Risk Factors and Prognostic Indicators. Elite Journal of Laboratory Medicine, 2024; 2(8): 17-28

6. Bone Marrow Findings

Bone marrow evaluation provides valuable prognostic information. Findings such as the degree of hypocellularity, the presence of dysplastic changes, and the extent of cellular infiltration can help determine the severity and underlying causes of AA. Bone marrow biopsy results assist in differentiating between primary AA and secondary causes related to HIV or other conditions, guiding treatment decisions.[78-81]

7. Genetic and Epigenetic Factors

Genetic and epigenetic factors can influence the prognosis of AA in HIV-positive patients. Variations in genes involved in hematopoiesis and immune regulation may affect susceptibility to AA and response to treatment. Epigenetic modifications resulting from chronic HIV infection can also impact gene expression related to hematopoiesis.[82-83]

8. Immune Reconstitution Inflammatory Syndrome (IRIS)

Immune Reconstitution Inflammatory Syndrome (IRIS) can occur in HIV-positive patients undergoing ART, leading to an exaggerated inflammatory response that affects the bone marrow. IRIS may worsen AA or complicate its management. Monitoring for signs of IRIS and managing it appropriately is important for optimizing patient outcomes and addressing potential complications.[84-85]

9. Treatment-Related Factors

The choice of treatment for AA, including immunosuppressive therapy, HSCT, or supportive care, significantly impacts prognosis. Factors such as the patient's response to immunosuppressive agents, the success of HSCT, and the management of transfusion-related complications influence overall outcomes. Tailoring treatment based on individual responses and tolerability is essential for improving prognosis.[86]

10. Overall Health Status

Overall health status, including nutritional status, comorbid conditions, and functional performance, affects prognosis. Malnutrition and poor functional status can exacerbate AA and impact treatment outcomes. Ensuring comprehensive care that addresses these aspects is crucial for enhancing prognosis and supporting patient well-being.[87]

Current Management Approaches

Management of AA in HIV-positive patients involves a combination of addressing the underlying HIV infection and treating the AA itself. This includes optimizing ART to achieve viral suppression, managing co-infections, and considering therapies specific to AA such as immunosuppressive treatments or hematopoietic stem cell transplantation. The management approach must be individualized based on the patient's overall health, risk factors, and response to therapy.[86-87]

Conclusion

The management of aplastic anemia (AA) in HIV-positive patients is a complex and multifaceted challenge that requires a careful balancing of treatments for both conditions. The interplay between HIV and AA necessitates a comprehensive approach that integrates effective antiretroviral therapy (ART), targeted immunosuppressive treatment, supportive care, and, in some cases, hematopoietic stem cell transplantation (HSCT). Key to successful management is the continuous monitoring of HIV viral load and CD4+ counts, which directly influence the progression and treatment of AA. Addressing co-infections and comorbidities is crucial, as these factors can exacerbate bone marrow suppression and complicate the clinical course of AA. The incorporation of supportive care measures, including transfusions and infection prophylaxis, helps in managing the symptoms of AA and improving patient outcomes. Nutritional support plays a vital role in addressing deficiencies that can further impair hematopoiesis.

References

1. Furlong E, Carter T. Aplastic anaemia: Current concepts in diagnosis and management. Journal of paediatrics and child health. 2020;56(7):1023-1028.
2. Chichetto NE, Polanka BM, So-Armah KA, Sung M, Stewart JC, Koethe JR, Edelman EJ, Tindle HA, Freiberg MS. Contribution of behavioral health factors to non-AIDS-related comorbidities: an updated review. Current HIV/AIDS Reports. 2020; 17:354-372.
3. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. Elite Journal of HIV, 2024; 2(1): 65-78
4. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
5. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. Elite Journal of Laboratory Medicine, 2024; 2(1): 46-58
6. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. Elite Journal of Nursing and Health Science, 2024; 2(1):21-31
7. Obeagu EI, GU Obeagu. Unmasking the Truth: Addressing Stigma in the Fight Against HIV. Elite Journal of Public Health, 2024; 2 (1): 8-22
8. Obeagu EI, Obeagu GU. Platelet-Driven Modulation of HIV: Unraveling Interactions and Implications. Journal home page: http://www. journalijiar. com. 2024;12(01).
9. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. Elite Journal of Medicine, 2024;2(1): 35-46
10. Obeagu EI, Obeagu GU. Implications of B Lymphocyte Dysfunction in HIV/AIDS. Elite Journal of Immunology, 2024; 2(1): 34-46
11. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. Elite Journal of HIV, 2024; 2(1): 1-15
12. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. Elite Journal of Health Science, 2024; 2(1): 33-42

Citation: Obeagu EI, Kanu SN. Aplastic Anemia in HIV: Risk Factors and Prognostic Indicators. Elite Journal of Laboratory Medicine, 2024; 2(8): 17-28

13. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. Elite Journal of Immunology, 2024; 2(1): 47-64
14. Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. Elite Journal of Immunology, 2024; 2(1): 1-13
15. Felker-Kantor EA, Wallace ME, Madkour AS, Duncan DT, Andrinopoulos K, Theall K. HIV stigma, mental health, and alcohol use disorders among people living with HIV/AIDS in New Orleans. Journal of urban health. 2019; 96:878-888.
16. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. Asian J Dental Health Sci 2024;4(1):38-44. Available from: http://ajdhs.com/index.php/journal/article/view/63
17. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. Elite Journal of HIV, 2024; 2(2): 1-17
18. Obeagu EI, Obeagu GU.Understanding Hematocrit Fluctuations in HIV-Malaria Coinfection for Improved Management. Elite Journal of Public Health, 2024; 2 (1): 22-34
19. Skalski LM, Sikkema KJ, Heckman TG, Meade CS. Coping styles and illicit drug use in older adults with HIV/AIDS. Psychology of Addictive Behaviors. 2013;27(4):1050.
20. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. Elite Journal of Medicine, 2024; 2(2):104-115
21. Alum EU, Ugwu OP, Obeagu EI, Okon MB. Curtailing HIV/AIDS spread: impact of religious leaders. Newport International Journal of Research in Medical Sciences (NIJRMS). 2023;3(2):28-31.
22. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES). 2023;3(2):56-59.
23. Obeagu EI, Obeagu GU, Paul-Chima UO. Stigma Associated With HIV. AIDS: A Review. Newport International Journal of Public Health and Pharmacy (NIJPP). 2023;3(2):64-7.
24. Alum EU, Obeagu EI, Ugwu OP, Aja PM, Okon MB. HIV infection and cardiovascular diseases: the obnoxious duos. Newport International Journal of Research in Medical Sciences (NIJRMS). 2023;3(2):95-99.
25. Hill K, Kuo I, Shenoi SV, Desruisseaux MS, Springer SA. Integrated care models: HIV and substance use. Current HIV/AIDS Reports. 2023;20(5):286-295.
26. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. Elite Journal of Laboratory Medicine, 2024; 2(1): 33-45
27. Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. Elite Journal of Medicine, 2024; 2(1):10-22
28. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. Asian J Dental Health Sci [Internet]. 2023 Jun. 15 [cited 2024 Sep. 7];3(2):7-14. Available from: http://ajdhs.com/index.php/journal/article/view/39

29. Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children Under 5 with Coexisting HIV and Severe Malaria: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):9-19.
30. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. Elite Journal of HIV, 2024; 2(1): 16-30
31. Alum EU, Obeagu EI, Ugwu OP, Samson AO, Adepoju AO, Amusa MO. Inclusion of nutritional counseling and mental health services in HIV/AIDS management: A paradigm shift. Medicine. 2023 Oct 13;102(41):e35673.
32. Obeagu EI, Obeagu, GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. Elite Journal of Scientific Research and Review, 2024; 2(1): 37-50
33. Obeagu EI, Obeagu GU. Eosinophil Dynamics in Pregnancy among Women Living with HIV: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024;10(1):11-24.
34. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Neutrophil Dynamics: Unveiling Their Role in HIV Progression within Malaria Patients. Journal home page: http://www. journalijiar. com.;12(01).
35. Goodwin M. Black markets: the supply and demand of body parts. Cambridge University Press; 2006.
36. Obeagu EI, Obeagu GU. Eosinophilic Changes in Placental Tissues of HIV-Positive Pregnant Women: A Review. Elite Journal of Laboratory Medicine, 2024; 2(1): 14-32
37. Obeagu EI, Obeagu, GU. P-Selectin and Platelet Activation in HIV: Implications for Antiviral Therapy. Elite Journal of Scientific Research and Review, 2024; 2(1): 17-41
38. Obeagu EI, Obeagu GU. The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):30-40.
39. Obeagu EI, Anyiam AF, Obeagu GU. Erythropoietin Therapy in HIV-Infected Individuals: A Critical Review. Elite Journal of HIV, 2024; 2(1): 51-64
40. Obeagu EI, Obeagu GU. Strength in Unity: Building Support Networks for HIV Patients in Uganda . Elite Journal of Medicine, 2024; 2(1): 1-16
41. Mandania EW. Haematological and Immunological Abnormalities in People Living With HIV: A Review. Journal of Medical and Biomedical Laboratory Sciences Research. 2024;4(1).
42. Obeagu EI, Obeagu, GU. The Crucial Role of Erythropoietin in Managing Anemia in HIV: A Review. Elite Journal of Scientific Research and Review, 2024; 2(1): 24-36
43. Obeagu EI, Ubosi NI, Obeagu GU, Obeagu AA. Nutritional Strategies for Enhancing Immune Resilience in HIV: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):41-51.
44. Obeagu EI, Obeagu GU. Assessing Platelet Functionality in HIV Patients Receiving Antiretroviral Therapy: Implications for Risk Assessment. Elite Journal of HIV, 2024; 2(3): 14-26
45. Obeagu EI, Elamin EAI Obeagu GU. Understanding the Intersection of Highly Active Antiretroviral Therapy and Platelets in HIV Patients: A Review. Elite Journal of Haematology, 2024; 2(3): 111-117
46. Obeagu EI, Obeagu GU. Understanding ART and Platelet Functionality: Implications for HIV Patients. Elite Journal of HIV, 2024; 2(2): 60-73

Citation: Obeagu EI, Kanu SN. Aplastic Anemia in HIV: Risk Factors and Prognostic Indicators. Elite Journal of Laboratory Medicine, 2024; 2(8): 17-28

47. Obeagu EI, Obeagu GU. Understanding Immune Cell Trafficking in Tuberculosis-HIV Coinfection: The Role of L-selectin Pathways. Elite Journal of Immunology, 2024; 2(2): 43-59
48. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. Applied Sciences (NIJBAS). 2023;3(3).
49. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to Mothers with Severe Malaria, HIV, and Transfusion History: A Review. Elite Journal of Nursing and Health Science, 2024; 2(3): 38-58
50. Obeagu EI. Erythropoietin and the Immune System: Relevance in HIV Management. Elite Journal of Health Science, 2024; 2(3): 23-35
51. Obeagu EI, Obeagu GU. Anemia and Erythropoietin: Key Players in HIV Disease Progression. Elite Journal of Haematology, 2024; 2(3): 42-57
52. Obeagu EI, Obeagu GU. Optimizing Blood Transfusion Protocols for Breast Cancer Patients Living with HIV: A Comprehensive Review. Elite Journal of Nursing and Health Science, 2024; 2(2):1-17
53. Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. Elite Journal of Health Science, 2024; 2(2): 20-35
54. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. Elite Journal of Nursing and Health Science, 2024; 2(2): 5-15
55. American Psychiatric Association. Practice guideline for the treatment of patients with HIV/AIDS. American Psychiatric Pub; 2000.
56. Alum EU, Ugwu OP, Obeagu EI, Aja PM, Okon MB, Uti DE. Reducing HIV Infection Rate in Women: A Catalyst to reducing HIV Infection pervasiveness in Africa. International Journal of Innovative and Applied Research. 2023;11(10):01-6.
57. Obeagu EI, Obeagu GU. Immune Modulation in HIV-Positive Neonates: Insights and Implications for Clinical Management. Elite Journal of Nursing and Health Science, 2024; 2(3): 59-72
58. Obeagu EI, Obeagu GU. Advancements in HIV Prevention: Africa's Trailblazing Initiatives and Breakthroughs. Elite Journal of Public Health, 2024; 2 (1): 52-63
59. Sukumaran RK. Long-Term Follow-Up and Chronic Complications. Contemporary Bone Marrow Transplantation. 2021:641-665.
60. Obeagu EI, Obeagu GU. Platelet Aberrations in HIV Patients: Assessing Impacts of ART. Elite Journal of Haematology, 2024; 2(3): 10-24
61. Obeagu EI, Obeagu GU. The Role of L-selectin in Tuberculosis and HIV Coinfection: Implications for Disease Diagnosis and Management. Elite Journal of Public Health, 2024; 2 (1): 35-51
62. Obeagu EI, Obeagu GU. Harnessing B Cell Responses for Personalized Approaches in HIV Management. Elite Journal of Immunology, 2024; 2(2): 15-28
63. Obeagu EI, Obeagu GU. Unveiling the Role of Innate Immune Activation in Pediatric HIV: A Review. Elite Journal of Immunology, 2024; 2(3): 33-44

Citation: Obeagu EI, Kanu SN. Aplastic Anemia in HIV: Risk Factors and Prognostic Indicators. Elite Journal of Laboratory Medicine, 2024; 2(8): 17-28

64. Obeagu EI, Obeagu GU. Unraveling the Role of Eosinophil Extracellular Traps (EETs) in HIV-Infected Pregnant Women: A Review. Elite Journal of Nursing and Health Science, 2024; 2(3): 84-99
65. Lyimo RA, Stutterheim SE, Hospers HJ, de Glee T, van der Ven A, de Bruin M. Stigma, disclosure, coping, and medication adherence among people living with HIV/AIDS in Northern Tanzania. AIDS patient care and STDs. 2014;28(2):98-105.
66. Obeagu EI, Obeagu, GU. Impact of Blood Transfusion on Viral Load Dynamics in HIV-Positive Neonates with Severe Malaria: A Review. Elite Journal of Scientific Research and Review, 2024; 2(1): 42-60
67. Obeagu EI, Obeagu GU. Impact of Maternal Eosinophils on Neonatal Immunity in HIV-Exposed Infants: A Review. Elite Journal of Immunology, 2024; 2(3): 1-18
68. Obeagu EI, Obeagu GU. L-selectin and HIV-Induced Immune Cell Trafficking: Implications for Pathogenesis and Therapeutic Strategies. Elite Journal of Laboratory Medicine, 2024; 2(2): 30-46
69. Obeagu EI, Obeagu GU. Exploring the Role of L-selectin in HIV-related Immune Exhaustion: Insights and Therapeutic Implications. Elite Journal of HIV, 2024; 2(2): 43-59
70. Obeagu EI, Obeagu GU. P-Selectin Expression in HIV-Associated Coagulopathy: Implications for Treatment. Elite Journal of Haematology, 2024; 2(3): 25-41
71. Obeagu EI, Obeagu GU. P-Selectin and Immune Activation in HIV: Clinical Implications. Elite Journal of Health Science, 2024; 2(2): 16-29
72. Obeagu EI, Amaeze AA, Ogbu ISI, Obeagu GU. B Cell Deficiency and Implications in HIV Pathogenesis: Unraveling the Complex Interplay. Elite Journal of Nursing and Health Science, 2024; 2(2): 33-46
73. Obeagu EI, Obeagu, GU. Platelet Dysfunction in HIV Patients: Assessing ART Risks. Elite Journal of Scientific Research and Review, 2024; 2(1): 1-16
74. Banerjee N, Goodman ZT, McIntosh R, Ironson G. Cognition, coping, and psychological distress in HIV. AIDS and Behavior. 2022;26(4):1074-1083.
75. Grau LE, Griffiths-Kundishora A, Heimer R, Hutcheson M, Nunn A, Towey C, Stopka TJ. Barriers and facilitators of the HIV care continuum in Southern New England for people with drug or alcohol use and living with HIV/AIDS: perspectives of HIV surveillance experts and service providers. Addiction science & clinical practice. 2017; 12:1-4.
76. Yu Y, Luo D, Chen X, Huang Z, Wang M, Xiao S. Medication adherence to antiretroviral therapy among newly treated people living with HIV. BMC public health. 2018; 18:1-8.
77. Li H, Wu X, Shen J, Lou S. Perspective and experience of patients with aplastic anemia on medication adherence. Patient preference and adherence. 2023:2215-2225.
78. Beichler H, Grabovac I, Dorner TE. Integrated care as a model for interprofessional disease management and the benefits for people living with HIV/AIDS. International Journal of Environmental Research and Public Health. 2023;20(4):3374.
79. Rajabiun S, Tryon J, Feaster M, Pan A, McKeithan L, Fortu K, Cabral HJ, Borne D, Altice FL. The influence of housing status on the HIV continuum of care: results from a multisite study of patient navigation models to build a medical home for people living with HIV experiencing homelessness. American Journal of Public Health. 2018;108(S7):S539-45.
80. Dale SK, Safren SA. Striving towards empowerment and medication adherence (STEP-AD): a tailored cognitive behavioral treatment approach for black women living with HIV. Cognitive and Behavioral Practice. 2018;25(3):361-376.

Citation: Obeagu EI, Kanu SN. Aplastic Anemia in HIV: Risk Factors and Prognostic Indicators. Elite Journal of Laboratory Medicine, 2024; 2(8): 17-28

81. Ngcobo S, Scheepers S, Mbatha N, Grobler E, Rossouw T. Roles, barriers, and recommendations for community health workers providing community-based HIV Care in Sub-Saharan Africa: a review. AIDS Patient Care and STDs. 2022;36(4):130-144.
82. Obeagu EI, Ogu RIO, Ngwoke AO. Psychosocial Impact of Aplastic Anemia Diagnosis in HIV Patients: A Narrative Review. Elite Journal of Public Health, 2024; 2 (7): 35-46
83. Obeagu EI, Akinleye CA. Stabilizing Hemoglobin Levels: A Vital Aspect of Blood Transfusions in HIV Management. *Elite Journal of Haematology, 2024; 2(9):* 1-8
84. Obeagu EI, Akinleye CA. Promoting Fertility: Blood Transfusions and Reproductive Health in HIV-Positive Individuals. *Elite Journal of Haematology, 2024; 2(9):* 9-16
85. Obeagu EI, Akinleye CA. Minimizing Treatment-Related Depression: Blood Transfusions and Mental Health Support in HIV Care. Elite Journal of Public Health, 2024; 2 (7): 16-24
86. Obeagu EI, Akinleye CA. Promoting Social Integration: Blood Transfusions and Improved Social Well-being in HIV Patients. Elite Journal of Public Health, 2024; 2 (7): 25-34
87. Obeagu EI, Akinleye CA. Optimizing Physical Endurance: Blood Transfusions in HIV and the Improvement of Exercise Capacity. Elite Journal of Medicine, 2024; 2(9): 1-9

Citation: Obeagu EI, Kanu SN. Aplastic Anemia in HIV: Risk Factors and Prognostic Indicators. Elite Journal of Laboratory Medicine, 2024; 2(8): 17-28